Remdesivir is an antiviral that inhibits RNA-dependent RNA polymerases of coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a cornerstone of therapy for hospitalized patients with coronavirus disease 2019 (COVID-19), especially those worsening from a respiratory standpoint despite being started on antibiotics, dexamethasone, zinc, and vitamin C. This is a case report describing two COVID-19-positive patients with bradycardia after starting remdesivir. Once remdesivir was discontinued, one patient corrected to normal sinus rhythm, and the other continued with persistent bradycardia.
All Keywords
【저자키워드】 COVID-19, Remdesivir, arrythymia, adult hospital medicine, drug induced bradycardia, 【초록키워드】 Dexamethasone, coronavirus disease, Coronaviruses, coronavirus, therapy, Antiviral, Vitamin C, Antibiotics, Case report, Patient, RNA-dependent RNA polymerase, bradycardia, acute respiratory syndrome, worsening, inhibit, hospitalized patient, 【제목키워드】 persistent,
【저자키워드】 COVID-19, Remdesivir, arrythymia, adult hospital medicine, drug induced bradycardia, 【초록키워드】 Dexamethasone, coronavirus disease, Coronaviruses, coronavirus, therapy, Antiviral, Vitamin C, Antibiotics, Case report, Patient, RNA-dependent RNA polymerase, bradycardia, acute respiratory syndrome, worsening, inhibit, hospitalized patient, 【제목키워드】 persistent,